Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study

Background:Black ethnic groups have a higher breast cancer mortality than Whites. American studies have identified variations in tumour biology and unequal health-care access as causative factors. We compared tumour pathology, treatment and outcomes in three ethnic groups in young breast cancer patients treated in the United Kingdom.Methods:Women aged ⩽40 years at breast cancer diagnosis were recruited to the POSH national cohort study (MREC: 00/06/69). Personal characteristics, tumour pathology and treatment data were collected at diagnosis. Follow-up data were collected annually. Overall survival (OS) and distant relapse-free survival (DRFS) were assessed using Kaplan–Meier curves, and multivariate analyses were performed using Cox regression.Results:Ethnicity data were available for 2915 patients including 2690 (91.0%) Whites, 118 (4.0%) Blacks and 87 (2.9%) Asians. Median tumour diameter at presentation was greater in Blacks than Whites (26.0 mm vs 22.0 mm, P=0.0103), and multifocal tumours were more frequent in both Blacks (43.4%) and Asians (37.0%) than Whites (28.9%). ER/PR/HER2-negative tumours were significantly more frequent in Blacks (26.1%) than Whites (18.6%, P=0.043). Use of chemotherapy was similarly high in all ethnic groups (89% B vs 88.6% W vs 89.7% A). A 5-year DRFS was significantly lower in Blacks than Asians (62.8% B vs 77.0% A, P=0.0473) or Whites (62.8 B% vs 77.0% W, P=0.0053) and a 5-year OS for Black patients, 71.1% (95% CI: 61.0–79.1%), was significantly lower than that of Whites (82.4%, 95% CI: 80.8–83.9%, W vs B: P=0.0160). In multivariate analysis, Black ethnicity had an effect on DRFS in oestrogen receptor (ER)-positive patients that is independent of body mass index, tumour size, grade or nodal status, HR: 1.60 (95% CI: 1.03–2.47, P=0.035).Conclusion:Despite equal access to health care, young Black women in the United Kingdom have a significantly poorer outcome than White patients. Black ethnicity is an independent risk factor for reduced DRFS particularly in ER-positive patients.

[1]  A. Troxel,et al.  Regional and racial disparities in breast cancer-specific mortality. , 2006, Social science & medicine.

[2]  M. Rosato,et al.  Cancer incidence among first generation Scottish, Irish, West Indian and South Asian migrants living in England and Wales. , 1999, Ethnicity & health.

[3]  C. Fischbacher,et al.  Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001–2003 , 2006, British Journal of Cancer.

[4]  L. Atkins,et al.  Breast cancer awareness and barriers to symptomatic presentation among women from different ethnic groups in East London , 2011, British Journal of Cancer.

[5]  A. Gaedigk,et al.  Unique CYP2D6 activity distribution and genotype‐phenotype discordance in black Americans , 2002, Clinical pharmacology and therapeutics.

[6]  J. Ingleby Early onset of breast cancer in Black British women: how reliable are the findings? , 2008, British Journal of Cancer.

[7]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[8]  O. Olopade,et al.  Racial differences in genetic factors associated with breast cancer , 2003, Cancer Metastasis Review.

[9]  P. Rosenberg,et al.  Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. , 2009, Journal of the National Cancer Institute.

[10]  John Boyages,et al.  Multifocal and multicentric breast cancer: does each focus matter? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Dignam Differences in breast cancer prognosis among African‐American and Caucasian women , 2000, CA: a cancer journal for clinicians.

[12]  M. West,et al.  Racial differences in breast carcinoma survival , 2000, Cancer.

[13]  E. Taioli,et al.  A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. , 1995, Cancer research.

[14]  H. Becher,et al.  Widening disparity in survival between white and African‐American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system , 2003, Cancer.

[15]  H. Møller,et al.  Breast cancer incidence, stage, treatment and survival in ethnic groups in South East England , 2009, British Journal of Cancer.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  R. Wait,et al.  Age at presentation of African-American and Caucasian breast cancer patients. , 1999, Journal of the American College of Surgeons.

[18]  D. Altman,et al.  PROSPECTIVE STUDY OF OUTCOMES IN SPORADIC VERSUS HEREDITARY BREAST CANCER , 2004 .

[19]  S. Martino,et al.  Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Shoker Racial differences in breast carcinoma , 2000, Breast Cancer Research.

[21]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[22]  S. Duffy,et al.  Reply: Early onset breast cancer in black British women: a letter to the editor of British Journal of Cancer regarding early onset of breast cancer in a group of British black women , 2008, British Journal of Cancer.

[23]  Dawn L Hershman,et al.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.

[24]  G. Hortobagyi,et al.  Multifocal breast cancer in women ≤35 years old , 2007, Cancer.

[25]  D. Altman,et al.  Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. , 2013, Journal of the National Cancer Institute.

[26]  G M Clark,et al.  Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. , 1994, Journal of the National Cancer Institute.

[27]  Ahmedin Jemal,et al.  Trends in Breast Cancer by Race and Ethnicity , 2003, CA: a cancer journal for clinicians.

[28]  Ahmedin Jemal,et al.  Trends in Breast Cancer by Race and Ethnicity: Update 2006 , 2006, CA: a cancer journal for clinicians.

[29]  C. Caldas,et al.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen , 2010, Breast Cancer Research.

[30]  L. Newman,et al.  Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital , 1997, Annals of Surgical Oncology.

[31]  P. Aspinall The utility and validity for public health of ethnicity categorization in the 1991, 2001 and 2011 British Censuses. , 2011, Public health.

[32]  Mary A. Gerend,et al.  Social Determinants of Black-White Disparities in Breast Cancer Mortality: A Review , 2008, Cancer Epidemiology Biomarkers & Prevention.

[33]  Yulei He,et al.  The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care , 2011, Cancer.

[34]  A. Dalton,et al.  Some observations on the mitochondria of normal and neoplastic cells with the electron microscope. , 1949, Journal of the National Cancer Institute.

[35]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[36]  D. Schrag,et al.  Missed opportunities: racial disparities in adjuvant breast cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Nerenz,et al.  Comorbidity and survival disparities among black and white patients with breast cancer. , 2005, JAMA.

[38]  J. Griggs,et al.  Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  W Wood,et al.  Selection bias in clinical trials. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Bhopal,et al.  Negro, Black, Black African, African Caribbean, African American or what? Labelling African origin populations in the health arena in the 21st century , 2005, Journal of Epidemiology and Community Health.

[41]  J. Griggs,et al.  Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Ahmedin Jemal,et al.  Cancer Disparities by Race/Ethnicity and Socioeconomic Status , 2004, CA: a cancer journal for clinicians.

[43]  N. Roodi,et al.  Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. , 1998, Cancer research.

[44]  Bradford Ld CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[45]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[46]  N. Pavlidis,et al.  Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. , 2012, Cancer treatment reviews.

[47]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[48]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Jeffreys,et al.  Do lifestyle or social factors explain ethnic/racial inequalities in breast cancer survival? , 2009, Epidemiologic reviews.